CS MEDICA A/S Secures Sales Approval in Azerbaijan & Georgia, Valued at 1.17 mDKK

Successfully converting pipeline orders into sales through regulatory approval, while expanding the pipeline in the South Africa Region, valued at 2.5 mDKK post-registration.

CS MEDICA A/S, a Danish MedTech company specializing in pain management and autoimmune treatments, announces the successful completion of the registration process for its CANNASEN® medical device products in Azerbaijan and Georgia. The company is now ready for sales in these regions.

Since March 2024, CS MEDICA has been engaged in the registration process for its Pain & Arthritis Gel, Psoriasis Gel, and Nasal Night Spray with its distributor, Hippokrat LTD. While initially expected to be completed in July, the timeline was extended due to a new law that ultimately facilitated the approval process. Now, under updated Class I medical device regulations, the company has secured sales approval. With this clearance, CS MEDICA is set to fulfill its distribution agreement with Hippokrat LTD, shipping 33,528 units valued at 1.17 million DKK and successfully converting the order pipeline into active sales. 
 

Expanding Pipeline with New Distribution Partnership in the South Africa Region

CS MEDICA is also pleased to announce a new distribution agreement with Benotech in South Africa. This partnership begins the registration process for all nine products in the CANNASEN® portfolio, with an estimated 2-6 months lead time on product registration. The anticipated market launch is set for 2025, covering South Africa, Botswana, and Lesotho, with further expansion into Zambia and Kenya in 2026. The partnership with Benotech represents an additional pipeline opportunity, with an expected value of 2.5 million DKK for 45,900 products.